Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

@article{Scaltriti2010ClinicalBO,
  title={Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.},
  author={Maurizio Scaltriti and Sarat Chandarlapaty and Ludmila Prudkin and Claudia Monica Aura and Jos{\'e} Jim{\'e}nez and Pier Davide Angelini and Gertrudis S{\'a}nchez and M. E. Guzm{\'a}n and Josep Lluis Parra and Catherine L Ellis and Robert C. Gagnon and Maria Koehler and Henry G{\'o}mez and Charles Edward Geyer and David Cameron and Joaqu{\'i}n Arribas and Neal Rosen and Jos{\'e} Baselga},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 9},
  pages={2688-95}
}
PURPOSE A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…